Skip to main content
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Font Resize
+A
A
-A
Contrast
عربي
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Home
Search Results
Containing any of the words
Only of the type
All
calculators
Conference
covid pages
Marketed Products
Periodic Safety
Vaccine Safety
Annual Report
Awareness Campaign
Cosmetics standards Project
Cosmetics Warning
Drug Membership
Eservices
Event
Events
Hajj card
HAPC Committee Decisions
head of board
hpac-members
International Standard
Laboratories
Lists
List Registered Drugs
List Shortage Drug
Medical devices studies
Podcasts
portables service
Reference repositories drugs
Scientific Magazines and articles
Scientific reports and statement
sector committee
Sector Committee decisions
Speakers
Surveys
test
Warehouse
Awareness Article
Circulars
Clinical Trial
Drug Clinical Trial
Drug evaluation reports
Drug Log
Drug Safety Labeling
Excellent establishments list
Forms
Information List
List Drugs Withdrawal
List of hospital that reported sides effects
List Registered Pharmacies
List Under registration Drugs / Under committee review
Medical Report
Message
News
New SFDA Drug Approvals
Open Data
Regulations exceptions
Risk Minimization Activity
Risk Minimization Activity - New
Rumours
Safety Alert
service providing facilities
Standard
Standards Projects For Medical Devices
Warnings
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI)
Drug Clinical Trial
SFDA Detects 187 Violating Facilities During 1,959 Tours
News
A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents
Drug Clinical Trial
Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Drug Clinical Trial
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Drug Clinical Trial
"A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma"
Drug Clinical Trial
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Drug Clinical Trial
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma
Drug Clinical Trial
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma
Drug Clinical Trial
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE
Drug Clinical Trial
Pagination
First page
« First
Previous page
‹ Previous
…
الصفحة
75
الصفحة
76
الصفحة
77
الصفحة
78
Current page
79
الصفحة
80
الصفحة
81
الصفحة
82
الصفحة
83
…
Next page
Next ›
Last page
Last »